KVKatrijn Verhaeghen

Katrijn Verhaeghen

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Katrijn Verhaeghen has a total of 77 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Insulitis in the pancreas of non-diabetic organ donors under age 25 years with multiple circulating autoantibodies against islet cell antigens

    by Silke Smeets, Diedert Luc De Paep, Geert Stangé, Katrijn Verhaeghen, Bart Van der Auwera, Bart Keymeulen, Ilse Weets, Zhidong Ling, Peter In’t Veld, Frans Gorus

    Autoantibodies against islet cell antigens are routinely used to identify subjects at increased risk of symptomatic type 1 diabetes, but their relation to the intra-islet pathogenetic process that leads to positivity for these markers is poorly understood. We screened 556 non-diabetic organ donors (3 months to 24 years) for five different autoantibodies and found positivity in 27 subjects, 25 single- and two double autoantibody-positive donors. Histopathological screening of pancreatic tissue samples showed lesion characteristic for recent-onset type 1 diabetes in the two organ donors with a high-risk profile, due to their positivity for multiple autoantibodies and HLA-inferred risk. Inflammatory infiltrates (insulitis) were found in a small fraction of islets (<5%) and consisted predominantly of CD3+CD8+ T-cells. Islets with insulitis were found in close proximity to islets devoid of insulin-positivity; such pseudo-atrophic islets were present in multiple small foci scattered throughout the pancreatic tissue or were found to be distributed with a lobular pattern. Relative beta cell area in both single and multiple autoantibody-positive donors was comparable to that in autoantibody-negative controls. In conclusion, in organ donors under age 25 years, insulitis and pseudo-atrophic islets were restricted to multiple autoantibody-positive individuals allegedly at high risk of developing symptomatic type 1 diabetes, in line with reports in older age groups. These observations may give further insight into the early pathogenetic events that may culminate in clinically overt disease.


  • Open Access

    An analytical comparison of three immunoassay platforms for subpicomolar detection of protein biomarker GAD65

    by Olivier R Costa, Katrijn Verhaeghen, Sarah Roels, Geert Stangé, Zhidong Ling, Daniel Pipeleers, Frans K Gorus, Geert A Martens

    A disproportional increase of circulating GAD65 within hours from an intraportal islet allotransplantation has been validated as biomarker of beta cell loss and poor functional outcome. More sensitive assays are, however, needed to allow detection of episodes of subtle beta cell loss during late-stage graft rejection or in the peri-onset period of type 1 diabetes. We applied the same sandwich monoclonal antibody couple reactive towards the C- and N-terminus of GAD65 on three advanced immunoassay platforms—the Cytometric Bead Array (CBA, Becton, Dickinson and Company), ElectroChemiLuminescence ImmunoAssay (ECLIA, Meso Scale Discovery) and digital ELISA technology (Single Molecule Array—SIMOA, Quanterix. We then compared analytical performance (linearity, imprecision, limit of detection and functional sensitivity), correlation of results, and practicality. All evaluated techniques showed linearity up to at least 500 ng/dL (76.9 pmol/L). SIMOA achieved the lowest imprecision. The 3 platforms correlate well with each other and could all detect subpicomolar concentrations of GAD65 in plasma, but only SIMOA and CBA could quantify down to that range. SIMOA can achieve the highest sample throughput. The three methods tested allow sensitive detection of GAD65, but SIMOA appears best suited for automated quantification of subpicomolar concentrations.


  • Development of an Enhanced Sensitivity Bead-Based Immunoassay for Real-Time In Vivo Detection of Pancreatic β-Cell Death

    by Olivier R. Costa, Geert Stangé, Katrijn Verhaeghen, Benedicte Brackeva, Ellen Nonneman, Christiane S. Hampe, Zhidong Ling, Daniel Pipeleers, Frans K. Gorus, Geert A. Martens

    There is a clinical need for plasma tests to detect and quantify the in vivo destruction of pancreatic beta cells in type 1 diabetes. We previously developed a time-resolved fluorescence immunoassay to glutamate decarboxylase 65kDa (GAD65-TRFIA) that was able to detect the synchronous necrotic destruction of transplanted beta cells in the hours after their infusion in the liver. This GAD65-TRFIA, however, lacked sensitivity to detect continued beta cell rejection beyond this acute phase. The aim of present study was to gain at least an order of magnitude in analytical sensitivity by switching to Becton Dickinson Cytometric Bead Array (GAD65-CBA) enhanced sensitivity format, using the same couple of monoclonal antibodies. We compared the performances of GAD65-CBA and -TRFIA using CLSI protocols for linearity, imprecision, specificity, limit of detection (LoD) and functional sensitivity. We conducted a method comparison and assessed the biologic potential on samples from human recipients of islet grafts. The GAD65-CBA showed acceptable linearity and imprecision. Switching from TRFIA to CBA lowered functional sensitivity by a factor 35, and lowered LoD by a factor 11 with minimal need for method optimization. The enhanced sensitivity greatly expands the application domain of our biomarker and allowed for the first time to detect ongoing beta cell destruction up to at least 1 day post-islet transplantation. We conclude that the GAD65-CBA is suitable for biological and clinical assessment of the real-time destruction of beta cells in intraportal transplantation.


  • Potential of UCHL1 as biomarker for destruction of pancreatic beta cells

    by B. Brackeva, V. De Punt, G. Kramer, O. Costa, K. Verhaeghen, G. Stangé, J. Sadones, C. Xavier, J.M.F.G. Aerts, F.K. Gorus, et al.


  • Hyperglycemic Clamp and Oral Glucose Tolerance Test for 3-Year Prediction of Clinical Onset in Persistently Autoantibody-Positive Offspring and Siblings of Type 1 Diabetic Patients

    by Eric V. Balti, Evy Vandemeulebroucke, Ilse Weets, Ursule Van De Velde, Annelien Van Dalem, Simke Demeester, Katrijn Verhaeghen, Pieter Gillard, Christophe De Block, Johannes Ruige, et al.

    Context and Objective: In preparation of future prevention trials, we aimed to identify predictors of 3-year diabetes onset among oral glucose tolerance test (OGTT)- and hyperglycemic clamp-derived metabolic markers in persistently islet autoantibody positive (autoAb+) offspring and siblings of patients with type 1 diabetes (T1D). Design: The design is a registry-based study. Setting: Functional tests were performed in a hospital setting. Participants: Persistently autoAb+ first-degree relatives of patients with T1D (n = 81; age 5–39 years). Main Outcome Measures: We assessed 3-year predictive ability of OGTT- and clamp-derived markers using receiver operating characteristics (ROC) and Cox regression analysis. Area under the curve of clamp-derived first-phase C-peptide release (AUC5–10min; min 5–10) was determined in all relatives and second-phase release (AUC120–150min; min 120–150) in those aged 12–39 years (n = 62). Results: Overall, the predictive ability of AUC5–10min was better than that of peak C-peptide, the best predictor among OGTT-derived parameters (ROC-AUC [95%CI]: 0.89 [0.80–0.98] vs 0.81 [0.70–0.93]). Fasting blood glucose (FBG) and AUC5–10min provided the best combination of markers for prediction of diabetes within 3 years; (ROC-AUC [95%CI]: 0.92 [0.84–1.00]). In multivariate Cox regression analysis, AUC5–10min (P = .001) was the strongest independent predictor and interacted significantly with all tested OGTT-derived parameters. AUC5–10min below percentile 10 of controls was associated with 50–70% progression to T1D regardless of age. Similar results were obtained for AUC120–150min. Conclusions: Clamp-derived first-phase C-peptide release can be used as an efficient and simple screening strategy in persistently autoAb+ offspring and siblings of T1D patients to predict impending diabetes.


  • Open Access

    Preexisting Insulin Autoantibodies Predict Efficacy of Otelixizumab in Preserving Residual β-Cell Function in Recent-Onset Type 1 Diabetes

    by Simke Demeester, Bart Keymeulen, Leonard Kaufman, Annelien Van Dalem, Eric V. Balti, Ursule Van de Velde, Patrick Goubert, Katrijn Verhaeghen, Howard W. Davidson, Janet M. Wenzlau, et al.

    OBJECTIVE: Immune intervention trials in recent-onset type 1 diabetes would benefit from biomarkers associated with good therapeutic response. In the previously reported randomized placebo-controlled anti-CD3 study (otelixizumab; GlaxoSmithKline), we tested the hypothesis that specific diabetes autoantibodies might serve this purpose. RESEARCH DESIGN AND METHODS: In the included patients (n = 40 otelixizumab, n = 40 placebo), β-cell function was assessed as area under the curve (AUC) C-peptide release during a hyperglycemic glucose clamp at baseline (median duration of insulin treatment: 6 days) and every 6 months until 18 months after randomization. (Auto)antibodies against insulin (I[A]A), GAD (GADA), IA-2 (IA-2A), and ZnT8 (ZnT8A) were determined on stored sera by liquid-phase radiobinding assay. RESULTS: At baseline, only better preserved AUC C-peptide release and higher levels of IAA were associated with better preservation of β-cell function and lower insulin needs under anti-CD3 treatment. In multivariate analysis, IAA (P = 0.022) or the interaction of IAA and C-peptide (P = 0.013) independently predicted outcome together with treatment. During follow-up, good responders to anti-CD3 treatment (i.e., IAA+ participants with relatively preserved β-cell function [≥25% of healthy control subjects]) experienced a less pronounced insulin-induced rise in I(A)A and lower insulin needs. GADA, IA-2A, and ZnT8A levels were not influenced by anti-CD3 treatment, and their changes showed no relation to functional outcome. CONCLUSIONS: There is important specificity of IAA among other diabetes autoantibodies to predict good therapeutic response of recent-onset type 1 diabetic patients to anti-CD3 treatment. If confirmed, future immune intervention trials in type 1 diabetes should consider both relatively preserved functional β-cell mass and presence of IAA as inclusion criteria.


  • Clinical and biological characteristics of diabetic patients under age 40 in Cameroon: Relation to autoantibody status and comparison with Belgian patients

    by Milca Asanghanwa, Frans K. Gorus, Ilse Weets, Bart V. der Auwera, Folefac Aminkeng, Eric Mbunwe, Patrick Goubert, Katrijn Verhaeghen, Eugene Sobngwi, Janet M. Wenzlau, et al.


  • Alternative splicing and differential expression of the islet autoantigen IGRP between pancreas and thymus contributes to immunogenicity of pancreatic islets but not diabetogenicity in humans

    by V. Martijn de Jong, Joana R. F. Abreu, Annemarie A. Verrijn Stuart, Arno R. van der Slik, Katrijn Verhaeghen, Marten A. Engelse, Bianca Blom, Frank J. T. Staal, Frans K. Gorus, Bart O. Roep

    Aims/hypothesis Thymic expression of self-antigens during T-lymphocyte development is believed to be crucial for preventing autoimmunity. It has been suggested that G6PC2, the gene encoding islet-specific glucose-6-phosphatase catalytic subunit-related protein (IGRP), is differentially spliced between pancreatic beta cells and the thymus. This may contribute to incomplete elimination of IGRP-specific T lymphocytes in the thymus, predisposing individuals to type 1 diabetes. We tested whether specific splice variation in islets vs thymus correlates with loss of tolerance to IGRP in type 1 diabetes. Methods Expression of G6PC2 splice variants was compared among thymus, purified medullary thymic epithelial cells and pancreatic islets by RT-PCR. Differential immunogenicity of IGRP splice variants was tested in patients and healthy individuals for autoantibodies and specific cytotoxic T lymphocytes using radiobinding assays and HLA class I multimers, respectively. Results Previously reported G6PC2 splice variants, including full-length G6PC2, were confirmed, albeit that they occurred in both pancreas and thymus, rather than islets alone. Yet, their expression levels were profoundly greater in islets than in thymus. Moreover, three novel G6PC2 variants were discovered that occur in islets only, leading to protein truncations, frame shifts and neo-sequences prone to immunogenicity. However, autoantibodies to novel or known IGRP splice variants did not differ between patients and healthy individuals, and similar frequencies of IGRP-specific cytotoxic T lymphocytes could be detected in both patients with type 1 diabetes and healthy individuals. Conclusions/interpretation We propose that post-transcriptional variation of tissue-specific self-proteins may affect negative thymic selection, although this need not necessarily lead to disease.


  • LC–MS/MS identification of doublecortin as abundant beta cell-selective protein discharged by damaged beta cells in vitro

    by L. Jiang, B. Brackeva, G. Stangé, K. Verhaeghen, O. Costa, S. Couillard-Després, P. Rotheneichner, L. Aigner, C. Van Schravendijk, D. Pipeleers, et al.


  • Validation of an enzyme-linked immunosorbent assay for C-peptide analysis in Cameroon

    by M. Asanghanwa, F. van Genderen, K. Verhaeghen, B. Van der Auwera, E. Sobngwi, J.C. Mbanya, C. van Schravendijk